Your browser doesn't support javascript.
loading
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox, Christopher P; Ali, Ayesha S; McIlroy, Graham; Thust, Steffi; Martinez-Calle, Nicolás; Jackson, Aimee E; Hopkins, Louise M; Thomas, Catherine M; Kassam, Shireen; Wright, Josh; Chaganti, Sridhar; Smith, Jeffery; Chau, Ian; Culligan, Dominic; Linton, Kim M; Collins, Graham P; Ferreri, Andrés J M; Lewis, David; Davies, Andrew J; Johnson, Rod; Auer, Dorothee P; Cwynarski, Kate.
Afiliação
  • Fox CP; Department of Clinical Haematology, Nottingham University Hospitals National Health Service (NHS) Trust, Nottingham, United Kingdom.
  • Ali AS; Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom.
  • McIlroy G; Cancer Research UK (CRUK) Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Thust S; Cancer Research UK (CRUK) Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Martinez-Calle N; National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Jackson AE; Department of Clinical Haematology, Nottingham University Hospitals National Health Service (NHS) Trust, Nottingham, United Kingdom.
  • Hopkins LM; Cancer Research UK (CRUK) Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Thomas CM; Cancer Research UK (CRUK) Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Kassam S; Cancer Research UK (CRUK) Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Wright J; Department of Haemato-oncology, King's College Hospital NHS Foundation Trust, London, United Kingdom.
  • Chaganti S; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Smith J; Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Chau I; Department of Clinical Haematology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
  • Culligan D; Haemato-Oncology Unit, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Linton KM; Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
  • Collins GP; Haematology and Transplant Unit, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Ferreri AJM; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Lewis D; Lymphoma Unit, Department of Onco-Haematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Davies AJ; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom.
  • Johnson R; Southampton CRUK/National Institute for Health Research (NIHR) Experimental Cancer Medicines, University of Southampton, Southampton, United Kingdom.
  • Auer DP; Department of Clinical Haematology, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Cwynarski K; Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom.
Blood Adv ; 5(20): 4073-4082, 2021 10 26.
Article em En | MEDLINE | ID: mdl-34464973
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos